Public investment in research conducted by the National Institutes of Health (NIH) underlies discoveries in personalized medicine that ultimately provide better treatments to patients. Investment in the U.S. Food and Drug Administration (FDA), which serves as the gateway for many personalized medicine products entering the market, is equally important to facilitate patient access to personalized medicine. Consistent and robust funding for both agencies thus ensures personalized medicine will deliver on its promise for patients and the U.S. health system.
In February of 2018, U.S. President Donald Trump proposed a significant increase to the budget for the U.S. Food and Drug Administration (FDA), which the Coalition applauded. However, even though Congress had recently voted to approve an increase of about $2 billion to the National Institutes of Health (NIH)’s budget from FY 2017, the President’s proposal allocated an amount to NIH that was roughly equivalent to FY 2017 funding levels. Advancement in personalized medicine depends on the strength of both agencies.
PMC advocated for robust funding for the NIH and FDA through outside witness testimonies submitted to subcommittees of the U.S. House and Senate Appropriations Committee. To align its members in advocating for NIH and FDA funding, PMC also disseminated talking points to its members.
In May of 2017, U.S. President Donald Trump proposed an 18 percent cut to the National Institutes of Health (NIH)'s 2018 budget for biomedical research.
PMC remains committed to consistent and sufficient funding for NIH's work, which provides a foundation for innovation in personalized medicine. The Coalition called on the U.S. Congress to reject the President's proposed cut to NIH's budget.